Cyclic Peptides in Drug Discovery

Introduction

Cyclic peptides occupy a distinctive niche in drug discovery, bridging the chemical space between small molecules and biologics. Their conformational constraint reduces conformational entropy of the unbound state, which can enhance target binding affinity relative to linear counterparts. Furthermore, cyclization eliminates both N- and C-terminal charges, reducing susceptibility to exopeptidase degradation and improving metabolic stability. Despite these advantages, achieving adequate cell permeability remains the central pharmacological challenge for cyclic peptide therapeutics.

Head-to-Tail Cyclization

The most straightforward cyclic peptide topology involves amide bond formation between the N-terminal amino group and C-terminal carboxylate, generating a macrocyclic backbone. This head-to-tail (H2T) topology restricts backbone flexibility and can pre-organize the peptide into bioactive conformations that complement target binding pockets. Macrocyclic ring sizes of 7–14 residues are common for drug-like cyclic peptides, with larger rings (>14 residues) more closely resembling the conformational properties of linear peptides. Synthetic approaches include on-resin cyclization using DIC/HOBt or pentafluorophenyl ester activation, solution-phase macrolactamization, and native chemical ligation for larger sequences. The success of approved cyclic peptide drugs—including cyclosporine A (11 residues), vancomycin (heptapeptide core), and octreotide (8 residues)—validates the pharmaceutical viability of this structural class.

Stapled Peptides

Hydrocarbon stapling introduces a conformational constraint through a covalent crosslink between non-adjacent side chains, typically at i and i+3 or i and i+7 positions. The resulting staple locks the peptide into an α-helical conformation, enhancing both binding affinity and proteolytic resistance while reducing the polar surface area available for hydrogen bonding to water. The hydrocarbon staple also increases the proportion of hydrophobic surface area, which can dramatically improve cell permeability. Pioneering work demonstrated that all-hydrocarbon-stapled peptides targeting intracellular protein-protein interactions—such as the p53-MDM2 interaction—achieve nanomolar binding affinity and cellular uptake without requiring membrane-disruptive sequences. Clinical development of ALRN-6924, a stapled peptide MDM2/MDMX inhibitor, illustrates the therapeutic translation of this technology.

Cell Permeability Strategies

Achieving passive membrane diffusion of cyclic peptides requires simultaneous optimization of multiple physicochemical parameters. The “beyond rule of 5” framework recognizes that cyclic peptides can traverse membranes despite molecular weights exceeding 500 Da and high polar surface area through intramolecular hydrogen bonding, which shields polar groups from solvent. Proline incorporation can induce turns that facilitate intramolecular H-bond networks. N-methylation of backbone amides at key positions reduces both H-bond donor capacity and desolvation penalty. Lipophilic side-chain modifications—including N-alkylation, fatty acid conjugation, and incorporation of non-natural hydrophobic amino acids—partition peptides into lipid bilayers. The chameleon-like conformational switching between hydrophilic and hydrophobic states observed in some cyclic peptides further facilitates transmembrane transport.

Conclusion

Cyclic peptides offer unique therapeutic opportunities for modulating intracellular targets that are intractable to small molecules and biologics alike. Continued advances in computational design, macrocyclization chemistry, and permeability prediction are accelerating the drug-like optimization of this promising molecular class.